LL-37 research: what’s known about cathelicidin.

Why we frame this as “what research shows” instead of promising benefits

LL-37 is a regulated bulk substance in a current FDA classification, and there are no approved LL-37 drug products. PepScribe does not sell or recommend LL-37 as a commercial product. More importantly, the underlying biology disqualifies the standard “here are the benefits” framing that works for some peptides.

LL-37 does not have a single linear effect that scales with dose. It is a multifunctional immune effector whose net effect depends on local concentration, the proteolytic environment, the disease context, and what else is happening in the surrounding tissue. The same peptide that supports host defense in normal physiology contributes to rosacea pathology, drives psoriasis-associated dendritic cell activation, and is elevated in rheumatoid synovium.

The honest framing is therefore: here is what research has documented about LL-37 across several domains, what mechanisms appear well-established, where the evidence is thinner, and how clinicians frame the molecule in 2026.

The antimicrobial mechanism in detail

The original interest in LL-37 came from its activity against bacteria, and that activity is real, broad-spectrum, and biophysically well-characterized.

Gram-positive bacteria

LL-37 has documented in vitro activity against several Gram-positive pathogens, including Staphylococcus aureus (including some methicillin-resistant strains in laboratory conditions), Streptococcus species, and Enterococcus. The cationic peptide binds the negatively charged outer surface of the bacterial cell wall, disrupts the underlying lipid bilayer through carpet or toroidal-pore mechanisms, and causes membrane permeabilization.

Gram-negative bacteria

Activity against Gram-negative pathogens including Escherichia coli, Pseudomonas aeruginosa, and Klebsiella has been documented in vitro. LL-37 must first traverse or disrupt the lipopolysaccharide (LPS)- rich outer membrane before reaching the inner membrane. The peptide also binds free LPS, which can have separate consequences for endotoxin signaling.

Fungi and enveloped viruses

LL-37 has activity against Candida species and several other fungi in vitro. It has documented activity against enveloped viruses including influenza A and respiratory syncytial virus, attributed primarily to envelope disruption analogous to the bacterial mechanism. Activity against non-enveloped viruses is generally weaker.

The salt-sensitivity caveat

One important nuance: LL-37 antimicrobial activity is significantly reduced at physiological salt concentrations (around 150 mM NaCl) compared with the low-salt buffers used in many in vitro assays. This is a recurring theme in antimicrobial peptide research and one of the reasons in vitro potency does not always translate to in vivo efficacy. Several engineered LL-37 analogs have been designed specifically to retain activity in physiological salt, with mixed success.

Immunomodulatory effects

Direct microbial killing may not be the dominant mode of LL-37 action under physiological conditions. Substantial evidence supports a broader role as a host-defense signaling molecule. This was formalized by Robert Hancock and colleagues in the early 2000s, who argued that the immunomodulatory activities of cathelicidins were quantitatively more important than direct killing for many in vivo contexts.

Chemotaxis and immune cell recruitment

LL-37 is a potent chemoattractant for neutrophils, monocytes, and certain T cell subsets, principally through formyl peptide receptor 2 (FPR2, also called FPRL1). Mast cell chemotaxis and activation have also been documented. This recruitment activity amplifies the host response at sites of infection or tissue damage.

Dendritic cell function

LL-37 modulates dendritic cell differentiation, maturation, and antigen- presentation function. Depending on the context, this can shape downstream T cell priming. The directionality is again context-dependent: LL-37 can either support or constrain particular adaptive responses depending on what other signals are present.

LPS neutralization and TLR4 modulation

LL-37 binds LPS directly, which can dampen excessive TLR4 signaling and attenuate endotoxin-driven inflammation. This is one of the contexts in which LL-37 acts in an anti-inflammatory direction.

T cell responses and cytokine output

LL-37 influences the cytokine output of multiple immune cell types and shapes T cell responses both directly and indirectly through its effects on dendritic cells. The net effect on inflammation can be pro- or anti- inflammatory depending on dose, location, and context.

The consistent theme is dual-direction signaling: LL-37 is a host-defense amplifier in some contexts and an inflammation modulator in others. That dual nature matters when thinking about exogenous administration, because the same intervention will not produce a single, predictable effect across patients with different immune states.

Wound healing research

LL-37 has well-documented roles in skin and mucosal wound repair beyond its antimicrobial activity. Cathelicidin expression is upregulated at wound edges, and the peptide influences several aspects of the repair process.

Re-epithelialization

LL-37 promotes keratinocyte migration, a key step in closing skin wounds. Studies in human skin explant models have shown that blocking LL-37 impairs re-epithelialization, supporting a direct role in the repair process rather than a purely incidental upregulation.

Angiogenesis

LL-37 stimulates endothelial cell proliferation and capillary tube formation, with the angiogenic activity mediated through FPR2 signaling. Adequate vascular supply is a rate-limiting step in many wound healing contexts, so this mechanism is therapeutically interesting in chronic wound research.

Mucosal repair

Beyond skin, cathelicidin biology has been studied in gastrointestinal and airway mucosal repair, with broadly similar themes: induction at sites of damage, contribution to barrier restoration, and antimicrobial coverage of exposed tissue during the repair window.

Translational status

Topical LL-37 and engineered analogs have been studied in chronic wound models, including venous leg ulcer pilot work. The clinical pipeline is modest, with no approved LL-37 product as of 2026. The translational challenge is partly that native LL-37 is degraded too quickly in wound fluid to maintain therapeutic concentrations, which is why engineered analog programs have received the more substantive clinical investment.

Inflammatory skin conditions: where LL-37 dysregulation matters in opposing directions

Few molecules show as cleanly opposite roles in related conditions as LL-37 does in atopic dermatitis versus rosacea and psoriasis. This is the part of the literature most often misrepresented in popular content.

Atopic dermatitis: relative LL-37 deficiency

Lesional atopic dermatitis skin shows reduced LL-37 and reduced human beta- defensin-2 expression compared with psoriasis. The classical reference for this finding is the work of Donald Leung and colleagues. The relative cathelicidin deficiency contributes to the elevated rate of bacterial and viral skin infection seen in atopic dermatitis patients, including eczema herpeticum (severe disseminated herpes simplex skin infection that is particularly associated with atopic dermatitis).

Rosacea: aberrant LL-37 processing

Rosacea-affected skin shows elevated kallikrein 5 (KLK5) protease activity that produces non-canonical LL-37 fragments. These aberrant fragments drive inflammation and contribute to the vascular dysfunction characteristic of the disease. The pathology is not simply “more LL-37” but “wrong LL-37,” which is an important distinction. Therapeutic strategies in rosacea aimed at this axis target the protease activity rather than augmenting cathelicidin levels.

Psoriasis: LL-37 as a self-DNA chaperone

LL-37 is elevated in psoriatic plaques. More importantly, LL-37 forms complexes with self-DNA released from damaged cells. These complexes activate plasmacytoid dendritic cells via TLR9 and contribute to the inflammatory cascade that drives psoriatic disease. This mechanism, mapped in the late 2000s, established LL-37 as a participant in autoimmune-flavored inflammation, not merely an antimicrobial bystander.

Why this matters for thinking about exogenous LL-37

Augmenting LL-37 systemically in someone with subclinical or undiagnosed rosacea, psoriasis, or related disease is a plausible mechanism for triggering or worsening pathology. The same intervention that might support host defense in one patient could provoke inflammation in another. This is the central reason any clinical use of exogenous LL-37 demands careful patient selection and monitoring, and it is the reason gray-market self-administration carries risks that are not just theoretical.

The vitamin D / innate immunity story

The vitamin D / cathelicidin axis is one of the most clearly characterized examples of a nutrient directly regulating an innate immune effector. The mechanism, established in the foundational 2006 Sciencepaper by Liu PT and colleagues (“Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response,” Science 2006;311(5768):1770-3), runs through the vitamin D response element in the CAMP gene promoter.

The implications of this axis are practical:

• Vitamin D status influences cathelicidin biology. Patients with low 25-hydroxyvitamin D generate less LL-37 in macrophage models challenged with mycobacterial antigens. This is a mechanistic link, not a vague association.
• Tuberculosis susceptibility. Vitamin D deficiency has been associated with increased susceptibility to tuberculosis for over a century, and the cathelicidin pathway provides one mechanistic explanation. Several clinical trials have studied vitamin D supplementation in tuberculosis treatment with mixed results, reflecting the complexity of in vivo immunology.
• Respiratory infection biology. Observational studies have linked vitamin D status to incidence and severity of various respiratory infections. The cathelicidin axis is one of several plausible mechanisms underlying this association.
• Skin barrier biology. Keratinocyte cathelicidin expression also depends on vitamin D, which connects systemic vitamin D status to skin innate defense.

For most patients in 2026, the vitamin D / cathelicidin axis is the most evidence-supported way to influence LL-37 biology. Optimizing vitamin D status under medical evaluation, when deficiency is documented, is a clinically actionable intervention. Direct administration of exogenous LL-37 is not.

Antibiotic-resistant infection research interest

Cationic antimicrobial peptides, including LL-37, have received sustained research interest as a possible response to the rising challenge of antibiotic-resistant bacterial infections. The reasons are mechanistic:

• Membrane-targeting mechanism. Because LL-37 acts on the bacterial lipid bilayer rather than a specific enzyme or ribosomal target, the classical resistance pathways that compromise small-molecule antibiotics (target mutation, efflux, enzymatic degradation) do not transfer cleanly.
• Broad spectrum. Gram-positive, Gram-negative, fungal, and viral activity in a single molecule is attractive for empirical use cases.
• Innate origin. The molecule is part of human physiology, which can simplify some immunogenicity and safety considerations relative to xenobiotic compounds.

The translational reality has been harder than the mechanistic case suggests. Native LL-37 is salt-sensitive, proteolytically labile, cytotoxic at high concentrations, and immunomodulatory in ways that complicate dose selection. Resistance, while not following classical pathways, has been reported in multiple bacterial species through reduced membrane affinity, peptide degradation, and other adaptations. Engineered LL-37 analogs have been designed to address some of these limitations, but no analog has yet achieved approval for an antibiotic-resistant infection indication.

The field remains active, and cathelicidin-derived therapeutics are part of a broader pipeline of antimicrobial peptide programs. They are not, in 2026, a clinically available antibiotic substitute, and any framing that suggests otherwise is ahead of the evidence.

The “right amount” problem

With most peptides, dose-response questions are about finding the level that produces the desired effect with acceptable safety. With LL-37, the question is more pointed: too little is associated with infection susceptibility, too much is associated with inflammatory and autoimmune disease, and the appropriate amount depends on what the body is already doing.

This creates several specific challenges for thinking about exogenous LL-37 administration:

• No validated dose-response in humans. No clinical protocol has established what dose, route, or duration of exogenous LL-37 produces a defined therapeutic effect for a defined indication, in a way that has survived randomized evaluation.
• Bypassing endogenous regulation. The body normally generates LL-37 in tightly compartmentalized fashion, with cleavage occurring at the right place and time and proteolytic degradation handling clearance. Exogenous administration short-circuits that regulation. Engineered analogs designed to resist degradation amplify this effect.
• Pre-existing disease unmasking. In a patient with subclinical psoriasis, rosacea, lupus-spectrum autoimmunity, or another LL-37-elevated condition, augmenting cathelicidin could trigger or accelerate symptomatic disease.
• Cytotoxicity threshold. The therapeutic window between antimicrobial activity and host cell damage is narrower than for most clinical antibiotics, so dosing errors carry meaningful biological consequences.

The standard wellness-peptide framing of “take this to support immune function” does not survive contact with this biology. LL-37 is a molecule whose safe and effective therapeutic use, if achievable, requires much more controlled evaluation than has been completed for the native peptide.

Areas where evidence is thin

Several use cases for LL-37 circulate in peptide therapy communities and integrative medicine settings. The evidence supporting them is weaker than the rosacea, atopic dermatitis, wound healing, or vitamin D literature.

• Chronic Lyme and biofilm-associated infection. LL-37 has documented antimicrobial activity against some Borrelia species in vitro, and biofilm-disrupting properties have been studied in laboratory models. This does not translate to evidence that exogenous LL-37 treats post-treatment Lyme disease syndrome or chronic Lyme presentations in patients. The clinical use that exists rests on mechanistic plausibility plus case-series experience, not on randomized trials.
• COVID-19 and broader antiviral applications.Computational and biochemical work during the pandemic looked at LL-37 binding to SARS-CoV-2 spike protein and ACE2. None of this translated into approved therapeutics. Headline claims about LL-37 “treating” COVID-19 outran the data.
• Cancer applications. The oncology literature on LL-37 is genuinely bidirectional: pro-tumor effects in some models (ovarian, lung, breast), anti-tumor effects in others (colon, gastric). The direction depends on tumor type, receptor profile, and microenvironment. This is not a clean therapeutic story in either direction.
• General immune support. The framing of LL-37 as a generic immune booster is not supported by the underlying biology, which is much more context-dependent than the framing implies.
• Long-term safety of exogenous administration. Repeated dosing data in non-research populations, at the scale required to characterize rare adverse events or chronic effects, does not exist for native LL-37.

How clinicians frame LL-37 in 2026

Among clinicians who think carefully about peptide therapy, the framing of LL-37 in 2026 typically covers a few consistent points:

• The basic biology is real and important.LL-37 is a meaningful component of innate immunity, with well-characterized mechanism, regulation, and disease associations. Dismissing it as “unproven” is wrong.
• The translational evidence for exogenous LL-37 as a therapeutic is thin. No native LL-37 product has approval for any indication. The engineered analog pipeline is modest and unfinished.
• The dual-edged nature is the dominant clinical concern. Disease-elevation contexts (rosacea, psoriasis, lupus-spectrum, rheumatoid arthritis) are real and should be screened for before any consideration of cathelicidin augmentation.
• Vitamin D status is the most evidence- supported lever for influencing LL-37. Documented deficiency, evaluated medically, and corrected through standard dosing has the most defensible evidence base for a real clinical effect on the cathelicidin axis.
• Gray-market exogenous LL-37 is not a responsible substitute. Purity, dosing, and patient-selection problems compound the underlying biological complexity.

What this means for someone evaluating LL-37 today

If you have come to LL-37 looking for an immune lever you can pull, the honest summary is that the molecule is more complicated than that framing allows.

1. Get a full medical evaluation first. If you are dealing with chronic infection, post-infectious syndromes, recurrent skin issues, or other concerns that have led you to cathelicidin content, those issues deserve evaluation by a clinician who can assess the underlying biology and rule out conditions where LL-37 augmentation could make things worse.
2. Consider the vitamin D pathway first. If your vitamin D status has not been measured recently, that is the lowest-cost, highest-evidence way to influence cathelicidin biology. Dosing should be guided by measured 25-hydroxyvitamin D, not guesswork.
3. Address skin and infection issues through evidence-based pathways. Inflammatory skin conditions benefit from dermatologic evaluation. Infections benefit from evidence-based antimicrobial care, not gray-market peptides.
4. Recognize the regulatory state. LL-37 is in the FDA transitional post April 15 2026. PCAC review is pending. Final disposition is not settled. Any commercial source promising prescription LL-37 today is operating ahead of the regulatory framework.
5. Talk to a clinician, not a vendor. The questions worth asking about LL-37 (do I have a contraindicating condition, what is my vitamin D status, what is the underlying problem I am trying to solve) are clinical questions. Vendor marketing is not a substitute.

The cathelicidin literature is genuinely interesting, and the molecule has real biological consequence. The path from that interest to a safe and effective personal use case runs through medical evaluation, not through a peptide order form.